| Prev Close | 280.57 |
| Day Low/High | 277.58 / 284.46 |
| 52 Wk Low/High | 223.02 / 333.65 |
| Avg Volume | 1.60M |
| Exchange | NASDAQ |
| Shares Outstanding | 212.12M |
| Market Cap | 59.51B |
| EPS | 17.00 |
| P/E Ratio | 17.58 |
| Div & Yield | N.A. (N.A) |
Latest News
Nasdaq Leads Wall Street, Healthcare Stocks Rise on Senate Bill
Healthcare leads markets after the release of the Senate health plan.
Healthcare Leads as Stocks Turn Higher After Release of Senate Bill
Healthcare leads markets after Senate bill's release.
Dow and S&P 500 Dive Further From Records as Oil Price Rout Rages On
The S&P 500 and Dow slip on a crude oil slump.
Energy Sector Pressures the Dow and S&P 500 as Crude Selloff Steepens
Stocks are mixed as energy lags, health care leads.
Biogen To Report Second Quarter 2017 Financial Results And Strategic Update On July 25, 2017
Biogen Inc. (NASDAQ:BIIB) today announced it will report second quarter 2017 financial results and a strategic update on Tuesday, July 25, 2017, before the financial markets open.
Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer
Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17.
Biogen Upgraded at UBS on Alzheimer's Clinical Trial Progress
Positive clinical trial results and newly priced-in competition breed some optimism for UBS Analyst Carter Gould.
Jim Cramer: Another Rotation Out of Apple and Nvidia Is in the Cards
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
Why Alexion's Gain In the C-Suite Doesn't Bode Well For Biogen Takeout Prospects
Paul Clancy's move to another biotech firm could mean that there's nothing imminent in terms of Biogen being bought out, says Mizuho analyst Salim Syed.
Cramer: The Rotation Out of Apple and Nvidia Can Happen Again Today
We forget that a big hedge fund or mutual fund switching out of tech winners into everything else can roil the market.
Alexion Pops, Biogen Falls on Executive Shuffle; Epizyme Recovers As Investors Digest Phase 2 Data
Epizyme, Alexion Pharmaceuticals and XBiotech were among the biotech stock movers premarket trading on June 14.
Biogen CFO Bolts to Alexion
Chief accounting officer Greg Covino will serve as Biogen's interim principal financial officer while the firm searches for a new finance chief.
Biogen Announces Management Change
Biogen (NASDAQ: BIIB) announced today that Paul Clancy, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to join another biopharmaceutical company.
Lululemon Makes for Luluwavering; Rally Earns Some Trust: Jim Cramer's Best Blog
Jim Cramer discusses Lululemon and also mentions that the rally is earning some trust.
SPINRAZA® (Nusinersen) Approved In The European Union As First Treatment For Spinal Muscular Atrophy
The European Commission (EC) has granted a marketing authorization for SPINRAZA ® (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA), Biogen (NASDAQ:BIIB) announced today.
Biogen Announces Webcast Of Virtual Annual Meeting Of Stockholders
Biogen Inc. (NASDAQ: BIIB) announced today that the webcast of the Company's 2017 Annual Meeting of Stockholders will be held on Wednesday, June 7, 2017 at 9:00 a.
Celgene Stock Rises Premarket on Positive Late-Stage Test Results for Multiple Sclerosis Treatment
The trial enrolled 1,313 RMS patients in 21 countries for two years of study.
Biogen Acquires Remedy Pharmaceuticals' Late-Stage Drug CIRARA™
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced that Biogen (NASDAQ:BIIB)...
Biogen To Present At The Bernstein 33rd Annual Strategic Decisions Conference
Biogen Inc. (NASDAQ: BIIB) announced today that it will present at the Bernstein 33 rd Annual Strategic Decisions Conference.
Biogen Acquires Remedy Pharmaceuticals' CIRARA™ For Large Hemispheric Stroke
Biogen (NASDAQ: BIIB) announced today that it has completed an asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, CIRARA™ (intravenous glyburide).
Insiders Are Loading Up on Twitter, Biogen & More
Insiders at Twitter, Biogen and three other companies have been snapping up shares of their own stock lately.
Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Merger Buzz Drives Akorn to Top of Health Chart in April
Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.
High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids
Investors focus on a drug's efficacy and safety. Much less time is spent considering the importance of manufacturing, even though it is a vital step in the drug approval process.
